BioSpace News Archive

Bioverativ Inc., a Sanofi company, and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in hemophilia.

RogCon Biosciences (RogCon), a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, today announced preclinical data in a late-breaking poster presentation at the 2018 American Epilepsy Society Annual Meeting (AES) being held in New Orleans, LA November 30-December 4, 2018.

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated anemia who require regular red blood cell (RBC) transfusions.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1/2 LibrA T1 clinical trial of AUTO4, a developmental therapy for the treatment of relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL).

Presentation highlights clinical data in patients with relapsed or refractory hematologic malignancies

Encore Medical Education will publish the Best of SABCS® News highlighting the key findings presented at the 41st San Antonio Breast Cancer Symposium (SABCS®), to be held on December 4-8, 2018 in San Antonio, Texas, USA.

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented new data from the ongoing Phase 2 Zella 201 study evaluating the efficacy and safety of the investigational agent alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and mitoxantrone in patients with MCL-1-dependent relapsed or refractory (R/R) acute myeloid leukemia (AML)

100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from three ongoing clinical trials evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, Calif., December 1-4, 2018.

Every year on December 1, World AIDS Day reminds us to recognize the strength and resilience of people living with HIV, to remember those we have lost and to acknowledge both the important progress that has been made in addressing HIV and AIDS and the work that remains to be done.